Seeking Alpha

Immunomedics (IMMU -1.7%) reports that preclinical studies of its lead antibody drug candidate,...

Immunomedics (IMMU -1.7%) reports that preclinical studies of its lead antibody drug candidate, epratuzumab, show the drug to have a distinct way of reducing the immune response of B cells. B cells are responsible for producing antibodies that attack the patient's own body in autoimmune diseases such as lupus. The study results were presented at the 54th Annual Meeting of the American Society of Hematology.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)